{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:16:12Z","timestamp":1792167372113,"version":"4.4.0"},"reference-count":98,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.5551\/jat.rv17023","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T18:27:34Z","timestamp":1531333654000},"page":"771-782","source":"Crossref","is-referenced-by-count":480,"title":["Pathophysiology of Diabetic Dyslipidemia"],"prefix":"10.5551","volume":"25","author":[{"given":"Tsutomu","family":"Hirano","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Reaven GM, Greenfield MS. Diabetic hypertriglyceridemia: evidence for three clinical syndromes. Diabetes: 1981; 30 (Suppl 2): 66-75","DOI":"10.2337\/diab.30.2.S66"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003; 46: 733-749","DOI":"10.1007\/s00125-003-1111-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011, 96: 3448-3456","DOI":"10.1210\/jc.2011-0622"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Reaven GM: Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulinresistant individuals. Endocrinol Metab Clin North Am. 2005; 34: 49-62","DOI":"10.1016\/j.ecl.2004.12.001"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G: Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995; 95: 158-166","DOI":"10.1172\/JCI117633"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002; 23: 201-229","DOI":"10.1210\/edrv.23.2.0461"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Xiao C, Dash S, Morgantini C, Lewis GF: New and emerging regulators of intestinal lipoprotein secretion. Atherosclerosis. 2014; 233: 608-615","DOI":"10.1016\/j.atherosclerosis.2013.12.047"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Zilversmit D.B.: Atherogenesis: a postprandial phenomenon Circulation, 1979; 60: 473-485","DOI":"10.1161\/01.CIR.60.3.473"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bor\u00e9n J, Matikainen N, Adiels M, Taskinen MR. Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta. 2014; 431: 131-142","DOI":"10.1016\/j.cca.2014.01.015"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Duez H, Pavlic M, Lewis GF Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atheroscler Suppl. 2008; 9: 33-38","DOI":"10.1016\/j.atherosclerosissup.2008.05.013"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Duez H, Lamarche B, Val\u00e9ro R, Pavlic M, Proctor S, Xiao C, Szeto L, Patterson BW, Lewis GF: Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008: 117: 2369-2376","DOI":"10.1161\/CIRCULATIONAHA.107.739888"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Goldberg IJ Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996; 37: 693-707","DOI":"10.1016\/S0022-2275(20)37569-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Pyk\u00e4list\u00f6 OJ, Smith PH, Brunzell JD: Determinants of human adipose tissue lipoprotein lipase. Effect of diabetes and obesity on basal- and diet-induced activity. J Clin Invest. 1975; 56: 1108-1117","DOI":"10.1172\/JCI108185"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Bagdade JD, Porte D Jr, Bierman EL: Diabetic lipemia. A form of acquired fat-induced lipemia. N Engl J Med. 1967; 276: 427-433","DOI":"10.1056\/NEJM196702232760802"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T: Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J. Clin. Invest. 1995. 96: 2601-2605","DOI":"10.1172\/JCI118324"},{"key":"16","unstructured":"16) Cohn JS<sup>1<\/sup>, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, Russell RM, Schaefer EJ: Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J. Lipid Res. 1993; 34: 2033-2040"},{"key":"17","unstructured":"17) Karpe F<sup>1<\/sup>, Bell M, Bj\u00f6rkegren J, Hamsten A: et al. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 199-207"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL: Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J. Clin. Invest. 1973; 52: 1578-1585","DOI":"10.1172\/JCI107334"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Adiels M<sup>1<\/sup>, Matikainen N, Westerbacka J, S\u00f6derlund S, Larsson T, Olofsson SO, Bor\u00e9n J, Taskinen MR: Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis. 2012; 222: 222-228","DOI":"10.1016\/j.atherosclerosis.2012.02.001"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Davis HR, Veltri EP: Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb. 2007; 14: 99-108","DOI":"10.5551\/jat.14.99"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Lally S, Tan CY, Owens D, Tomkin GH: Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia. 2006; 49: 1008-1016","DOI":"10.1007\/s00125-006-0177-8"},{"key":"22","unstructured":"22) Dixon J.L, Ginsberg HN. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J. Lipid Res. 1993; 34: 167-179"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Bostrom, K., M. Wettesten, J. Boren, G. Bondjers, O. Wiklund, and S-O. Olofsson: Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in HepG2 cells. 1986; J. Biol. Chem. 261: 13800-13806","DOI":"10.1016\/S0021-9258(18)67090-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Barrows BR, Parks EJ. Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab. 2006; 91: 1446-1452","DOI":"10.1210\/jc.2005-1709"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Davis RA, Thrift RN, Wu CC, Howell KE: Apolipoprotein B is both integrated into and translocated across the endoplasmic reticulum membrane. Evidence for two functionally distinct pools. J Biol Chem. 1990; 265: 10005-10011","DOI":"10.1016\/S0021-9258(19)38770-8"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Dixon JL, Furukawa S, Ginsberg HN: Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem. 1991; 266: 5080-5086","DOI":"10.1016\/S0021-9258(19)67758-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ota T, Gayet C, Ginsberg HN: Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest. 2008; 118: 316-332","DOI":"10.1172\/JCI32752"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Zhang Y-L, Hernandez-Ono A, Ko C, Yasunaga K, Huang L-S, Ginsberg HN: Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids 1: Differential effects of delivering fatty acids via albumin or remnant-like emulsion particles. J Biol Chem. 2004; 279: 19362-1937","DOI":"10.1074\/jbc.M400220200"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Furukawa S, Hirano T: Rapid stimulation of apolipoprotein B secretion by oleate is not associated with cholesteryl ester biosynthesis in HepG2 cells. Biochim Biophys Acta. 1993; 1170: 32-37","DOI":"10.1016\/0005-2760(93)90172-6"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Wu X, Sakata N, Dixon J, Ginsberg HN: Exogenous VLDL stimulates apolipoprotein B secretion from HepG2 cells by both pre- and post-translational mechanisms. J Lipid Res. 1994; 35: 1200-1210","DOI":"10.1016\/S0022-2275(20)39963-6"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Field PA, Gibbons GF: Decreased hepatic expression of the low-density lipoprotein (LDL) receptor and LDL receptor-related protein in aging rats is associated with delayed clearance of chylomicrons from the circulation. Metabolism. 2000; 49: 492-498","DOI":"10.1016\/S0026-0495(00)80014-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acidsynthesis in the liver. J Clin Invest. 2002; 109: 1125-1131","DOI":"10.1172\/JCI0215593"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Melish J, Le NA, Ginsberg H, Steinberg D, Brown WV: Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins. Am J Phys. 1980; 239: E354-362","DOI":"10.1152\/ajpendo.1980.239.5.E354"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Wang Y, Viscarra J, Kim SJ, Sul HS: Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015; 16: 678-689","DOI":"10.1038\/nrm4074"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kubota N, Kubota T, Kajiwara E, Iwamura T, Kumagai H, Watanabe T, Inoue M, Takamoto I, Sasako T, Kumagai K, Kohjima M, Nakamuta M, Moroi M, Sugi K, Noda T, Terauchi Y, Ueki K, Kadowaki T: Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nat. Commun. 2016; 7: 12977","DOI":"10.1038\/ncomms12977"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Verg\u00e8s B: Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis 2010; 211: 353-360","DOI":"10.1016\/j.atherosclerosis.2010.01.028"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Vedala A, Wang W, Neese RA, Christiansen MP, Hellerstein MK: Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. J Lipid Res. 2006; 47: 2562-2574","DOI":"10.1194\/jlr.M600200-JLR200"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Skrha J, Haas T, Sindelka G, Pr\u00e1zn\u00fd M, Widimsk\u00fd J, Cibula D, Svacina S: Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab. 2004; 89: 135-141","DOI":"10.1210\/jc.2002-030024"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Durrington PN, Newton RS, Weinstein DB, Steinberg D: Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest. 1982; 70: 63-73","DOI":"10.1172\/JCI110604"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Sparks CE, Sparks JD, I Bolognino M, Salhanick A, Strumph PS, Amatruda JM: Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes. Metabolism. 1986; 35: 1128-1136","DOI":"10.1016\/0026-0495(86)90026-0"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD: Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J Biol Chem. 1997; 272: 30693-30702","DOI":"10.1074\/jbc.272.49.30693"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Allister EM, Borradaile NM, Edwards JY, Huff MW: Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes. 2005; 54: 1676-1683","DOI":"10.2337\/diabetes.54.6.1676"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kamagate A, Dong HH: Fox01 integrates insulin signaling to VLDL production. Cell Cycle. 2008; 7: 3162-3170","DOI":"10.4161\/cc.7.20.6882"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Lewis GF, Zinman B, Uffelman KD, Szeto L, Weller B, Steiner G: VLDL production is decreased to a similar extent by acute portal vs. peripheral venous insulin. Am J Physiol. 1994; 267: E566-572","DOI":"10.1152\/ajpendo.1994.267.4.E566"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alem\u00e1n JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR: Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis.Cell Metab. 2008; 7: 95-96","DOI":"10.1016\/j.cmet.2007.11.013"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Suga A, Hirano T, Inoue S, Tsuji M, Osaka T, Namba Y, Miura M, Adachi M: Plasma leptin levels and triglyceride secretion rates in VMH-lesioned obese rats: a role of adiposity. Am J Physiol. 1999; 276: E650-657","DOI":"10.1152\/ajpendo.1999.276.4.E650"},{"key":"47","unstructured":"47) Zhao SP, Bastiaanse EM, Hau MF, Smelt AH, Gevers Leuven JA, Van der Laarse A, Van&apos;t Hooft FM: Separation of VLDL subfractions by density gradient ultracentrifugation. J Lab Clin Med. 1995; 125: 641-649"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Verg\u00e8s B: Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015; 58: 886-899","DOI":"10.1007\/s00125-015-3525-8"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Malmstrom R, Packard CJ, Watson TD, Rannikko S, Caslake M,Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR: Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol. 1997; 17: 1454-1464","DOI":"10.1161\/01.ATV.17.7.1454"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Gill JM, Brown JC, Bedford D, Wright DM, Cooney J, Hughes DA, Packard CJ, Caslake MJ: Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis. 2004; 176: 49-56","DOI":"10.1016\/j.atherosclerosis.2004.04.022"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Adiels M, Olofsson SO, Taskinen MR, Bor\u00e9n J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008; 28: 1225-1236","DOI":"10.1161\/ATVBAHA.107.160192"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Hiukka A<sup>1<\/sup>, Fruchart-Najib J, Leinonen E, Hilden H, Fruchart JC, Taskinen MR: Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia. 2005; 48: 1207-1215","DOI":"10.1007\/s00125-005-1753-z"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Kohan AB: Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2015; 22: 119-125","DOI":"10.1097\/MED.0000000000000136"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Hirano T, Takahashi T, Saito S, Tajima H, Ebara T, Adachi M: Apoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein E. Am J Physiol Endocrinol Metab. 2001; 281: E665-669","DOI":"10.1152\/ajpendo.2001.281.4.E665"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Takahashi T, Hirano T, Okada K, Adachi M: Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice. Metabolism. 2003; 52: 1354-1359","DOI":"10.1016\/S0026-0495(03)00202-6"},{"key":"56","doi-asserted-by":"crossref","unstructured":"57) Lookene A, Beckstead JA, Nilsson S, Olivecrona G, Ryan RO: Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem 2005; 280: 25383-25387","DOI":"10.1074\/jbc.M501589200"},{"key":"57","doi-asserted-by":"crossref","unstructured":"58) Lee EC, Desai U, Gololobov G, Hong S, Feng X, Yu XC, Gay J, Wilganowski N, Gao C, Du LL, Chen J, Hu Y, Zhao S, Kirkpatrick L, Schneider M, Zambrowicz BP, Landes G, Powell DR, Sonnenburg WK: Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J Biol Chem. 2009; 284: 13735-13745","DOI":"10.1074\/jbc.M807899200"},{"key":"58","doi-asserted-by":"crossref","unstructured":"59) Betteridge DJ: Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab. 2007; 9: 640-647","DOI":"10.1111\/j.1463-1326.2007.00715.x"},{"key":"59","doi-asserted-by":"crossref","unstructured":"60) Kaumi T, Hirano T, Odaka H, Ebara T, Amano N, Hozumi T, Ishida Y, Yoshino G: VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone. Diabetes. 1996; 45: 806-811","DOI":"10.2337\/diabetes.45.6.806"},{"key":"60","doi-asserted-by":"crossref","unstructured":"61) Kageyama H, Hirano T, Okada K, Ebara T, Kageyama A, Murakami T, Shioda S, Adachi M: Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma. Biochem Biophys Res Commun. 2003; 305: 22-27","DOI":"10.1016\/S0006-291X(03)00663-6"},{"key":"61","doi-asserted-by":"crossref","unstructured":"62) Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN: Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005; 115: 1323-1332","DOI":"10.1172\/JCI200523219"},{"key":"62","doi-asserted-by":"crossref","unstructured":"63) Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ: Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 1993; 223: 53-71","DOI":"10.1016\/0009-8981(93)90062-9"},{"key":"63","doi-asserted-by":"crossref","unstructured":"64) Campos E, Kotite L, Blanche P, Mitsugi Y, Frost PH, Masharani U, Krauss RM, Havel RJ: Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human blood plasma. J Lipid Res. 2002; 43: 365-374","DOI":"10.1016\/S0022-2275(20)30142-5"},{"key":"64","doi-asserted-by":"crossref","unstructured":"65) Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, Wilson PW: Framingham Offspring Study Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care. 2002; 25: 989-994","DOI":"10.2337\/diacare.25.6.989"},{"key":"65","doi-asserted-by":"crossref","unstructured":"66) Turner RC: The U.K. Prospective Diabetes Study. A review. Diabetes Care. 1998; 21 Suppl 3: C35-38","DOI":"10.2337\/diacare.21.3.C35"},{"key":"66","doi-asserted-by":"crossref","unstructured":"67) Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364: 685-696","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68) Krauss RM: All low-density lipoprotein particles are not created equal. Arterioscler Thromb Vasc Biol. 2014; 34: 959-961","DOI":"10.1161\/ATVBAHA.114.303458"},{"key":"68","doi-asserted-by":"crossref","unstructured":"69) Austin MA, King MC, Vranizan KM, Krauss RM: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990; 82: 495-506","DOI":"10.1161\/01.CIR.82.2.495"},{"key":"69","doi-asserted-by":"crossref","unstructured":"70) Berneis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002; 43: 1363-1379","DOI":"10.1194\/jlr.R200004-JLR200"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71) Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996; 276: 882-888","DOI":"10.1001\/jama.1996.03540110036029"},{"key":"71","doi-asserted-by":"crossref","unstructured":"72) Georgieva AM, van Greevenbroek MM, Krauss RM, Brouwers MC, Vermeulen VM, Robertus-Teunissen MG, van der Kallen CJ, de Bruin TW: Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol. 2004; 24: 744-749","DOI":"10.1161\/01.ATV.0000119681.47218.a4"},{"key":"72","doi-asserted-by":"crossref","unstructured":"73) Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D&apos;Agostino RB, Vasan RS, Robins SJ: Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113: 20-29","DOI":"10.1161\/CIRCULATIONAHA.105.567107"},{"key":"73","doi-asserted-by":"crossref","unstructured":"74) Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura T, Matsuzawa Y, Yamashita S: Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol. 2005; 25: 578-584","DOI":"10.1161\/01.ATV.0000155017.60171.88"},{"key":"74","doi-asserted-by":"crossref","unstructured":"75) Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Bor\u00e9n J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Stroes E, Taskinen MR, Tybj\u00e6rg-Hansen A, Watts GF, Wiklund O; European Atherosclerosis Society Consensus Panel: The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014; 2: 655-666","DOI":"10.1016\/S2213-8587(13)70191-8"},{"key":"75","doi-asserted-by":"crossref","unstructured":"76) Ito Y, Fujimura M, Ohta M, Hirano T: Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem. 2011; 57: 57-65","DOI":"10.1373\/clinchem.2010.149559"},{"key":"76","doi-asserted-by":"crossref","unstructured":"77) Arai H, Kokubo Y, Watanabe M, Sawamura T, Ito Y, Minagawa A, Okamura T, Miyamato Y: Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study. J Atheroscler Thromb. 2013; 20: 195-203","DOI":"10.5551\/jat.14936"},{"key":"77","doi-asserted-by":"crossref","unstructured":"78) Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, Couper D, Virani SS, Kathiresan S, Boerwinkle E, Ballantyne CM: Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014; 34: 1069-1077","DOI":"10.1161\/ATVBAHA.114.303284"},{"key":"78","doi-asserted-by":"crossref","unstructured":"79) Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J, Yoshino G: Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol. 2004; 24: 558-563","DOI":"10.1161\/01.ATV.0000117179.92263.08"},{"key":"79","doi-asserted-by":"crossref","unstructured":"80) Hayashi T, Koba S, Ito Y, Hirano T: Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels. Lipids Health Dis. 2017 26; 16: 21","DOI":"10.1186\/s12944-017-0417-6"},{"key":"80","doi-asserted-by":"crossref","unstructured":"81) Hirano T, Ito Y, Saegusa H, Yoshino G: A novel and simple method for quantification of small, dense LDL. J Lipid Res. 2003; 44: 2193-2201","DOI":"10.1194\/jlr.D300007-JLR200"},{"key":"81","doi-asserted-by":"crossref","unstructured":"82) HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J: Effects of extended-release niacin with laropiprant in high-risk patients N. Engl. J. Med. 2014; 371, 203-212","DOI":"10.1056\/NEJMoa1300955"},{"key":"82","doi-asserted-by":"crossref","unstructured":"83) Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events N.Engl. J. Med., 2007; 357: 2109-2122","DOI":"10.1056\/NEJMoa0706628"},{"key":"83","doi-asserted-by":"crossref","unstructured":"84) Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, H\u00f3lm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, K\u00f6nig IR, Fischer M, Heng stenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Sch\u00e4fer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O&apos;Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012; 380: 572-580","DOI":"10.1016\/S0140-6736(12)60312-2"},{"key":"84","doi-asserted-by":"crossref","unstructured":"85) Calabresi L, Franceschini G, Sirtori M, Gianfranceschi G, Werba P, Sirtori CR: Influence of serum triglycerides on the HDL pattern in normal subjects and patients with coronary artery disease. Atherosclerosis. 1990; 84: 41-48","DOI":"10.1016\/0021-9150(90)90006-5"},{"key":"85","doi-asserted-by":"crossref","unstructured":"86) Ito Y, Satoh N, Ishii T, Kumakura J, Hirano T: Development of a homogeneous assay for measurement of high-density lipoprotein-subclass cholesterol. Clin Chim Acta. 2014; 427: 86-93","DOI":"10.1016\/j.cca.2013.09.009"},{"key":"86","doi-asserted-by":"crossref","unstructured":"87) Maeda S, Nakanishi S, Yoneda M, Awaya T, Yamane K, Hirano T, Kohno N: Associations between small dense LDL, HDL subfractions (HDL2, HDL3) and risk of atherosclerosis in Japanese-Americans. J Atheroscler Thromb. 2012; 19: 444-452","DOI":"10.5551\/jat.11445"},{"key":"87","doi-asserted-by":"crossref","unstructured":"88) Fukui T, Hirano T: High-density lipoprotein subspecies between patients with type 1 diabetes and type 2 diabetes without \/ with intensive insulin therapy. Endocr J. 2012; 59: 561-569","DOI":"10.1507\/endocrj.EJ11-0329"},{"key":"88","doi-asserted-by":"crossref","unstructured":"89) Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011; 364: 127-135","DOI":"10.1056\/NEJMoa1001689"},{"key":"89","doi-asserted-by":"crossref","unstructured":"90) Srivastava RAK: Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease. Mol Cell Biochem. 2018; 440: 167-187","DOI":"10.1007\/s11010-017-3165-z"},{"key":"90","doi-asserted-by":"crossref","unstructured":"91) Hirano T: Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol. 2014; 18: 206-209","DOI":"10.1007\/s10157-013-0880-y"},{"key":"91","doi-asserted-by":"crossref","unstructured":"92) Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, Adachi M: Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. Atherosclerosis. 2008; 197: 154-158","DOI":"10.1016\/j.atherosclerosis.2007.03.015"},{"key":"92","doi-asserted-by":"crossref","unstructured":"93) Hirano T, Ookubo K, Kashiwazaki K, Tajima H, Yoshino G, Adachi M: Vascular endothelial markers, von Willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. Clin Chim Acta. 2000; 299: 65-75","DOI":"10.1016\/S0009-8981(00)00274-6"},{"key":"93","doi-asserted-by":"crossref","unstructured":"94) Kashiwazaki K, Hirano T, Yoshino G, Kurokawa M, Tajima H, Adachi M: Decreased release of lipoprotein lipase is associated with vascular endothelial damage in NIDDM patients with microalbuminuria. Diabetes Care. 1998; 21: 2016-2020","DOI":"10.2337\/diacare.21.11.2016"},{"key":"94","doi-asserted-by":"crossref","unstructured":"96) Mori Y, Hirano T, Nagashima M, Shiraishi Y, Fukui T, Adachi M: Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism. 2007; 56: 1714-1718","DOI":"10.1016\/j.metabol.2007.07.016"},{"key":"95","doi-asserted-by":"crossref","unstructured":"97) Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T: Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int Suppl. 1999; 71: S227","DOI":"10.1046\/j.1523-1755.1999.07159.x"},{"key":"96","doi-asserted-by":"crossref","unstructured":"98) Pennacchio LA, Rubin EM: Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol. 2003; 23: 529-534","DOI":"10.1161\/01.ATV.0000054194.78240.45"},{"key":"97","doi-asserted-by":"crossref","unstructured":"99) Hirano T, Hayashi T, Adachi M, Taira T, Hattori H: Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease. Metabolism. 2007; 56: 462-463","DOI":"10.1016\/j.metabol.2006.11.002"},{"key":"98","doi-asserted-by":"crossref","unstructured":"100) Clement LC, Mac\u00e9 C, Avila-Casado C, Joles JA, Kersten S, Chugh SS: Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome Nat Med, 2014; 14: 37-46","DOI":"10.1038\/nm.3396"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/9\/25_RV17023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T04:33:33Z","timestamp":1661574813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/25\/9\/25_RV17023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":98,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv17023","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}